Zealand Pharma A/S revised revenue guidance for the full year of 2022. Net product revenue from the sales of Zegalogue is expected to be DKK 11.5 million +/- 10%. This is a reduction of DKK 7.5 million from updated guidance issued on May 12, 2022, reflecting the completion of the Asset Purchase Agreement for V-Go with MannKind Corporation.

The company will no longer provide guidance on net product revenue associated with sales from that program.